High patient satisfaction for ocular hypotensives

Article

Glaucoma and ocular hypertension (OHT) patients are highly satisfied with ocular hypertensives, claims a recent investigation.

Glaucoma and ocular hypotension patients are highly satisfied with ocular hypotensives, claims a recent investigation.

A prospective, observational, cohort study, led by Professor Helen Danesh-Meyer, Department of Ophthalmology, University of Auckland, New Zealand, included 2541 patients with glaucoma or ocular hypotension. The Treatment Impact Patient Satisfaction Scale (TIPSS) was mailed to all patients during a three-month study period.

The questionnaire evaluated patient demographics topical ocular hypotensive use, number of medications used, frequency of administration, ease of use, class of medication, presence/severity of side effects, impact on quality of life and patient satisfaction. The main outcome measure was patient satisfaction and this was determined via univariate and multivariate analyses.

Of the patients who responded to the questionnaire, almost 80% claimed they were either 'very satisfied' or 'satisfied' with topical ocular hypotensives. Factors that affected patient satisfaction were identified as satisfaction with frequency of eye drop use, subjective convenience and ease of administration.

Overall, glaucoma and ocular hypotension patients are satisfied with topical ocular hypotensive medications. However, patient satisfaction could be further improved by focusing on medication convenience and ease of administration.

The abstract can be found in the latest issue of Clinical and Experimental Ophthalmology.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.